Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

By BioPharma Dive staff • July 24, 2026

Scribe secures $129M in a rare gene editing IPO

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.

By Ben Fidler • July 23, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

By Ben Fidler • July 22, 2026

Crystalys nets $130M more to push gout drug through late-stage tests

The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.

By Jonathan Gardner • July 22, 2026

Agios scraps sickle cell drug

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

By Jacob Bell • July 21, 2026

Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’

The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.

By Ben Fidler • July 21, 2026

Pain drugmaker Latigo outlines plans to go public

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

By Jacob Bell • July 20, 2026

Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

By Ben Fidler • July 20, 2026

[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

By BioPharma Dive's studioID • Updated May 26, 2026

Jasper gets a lifeline in merger with immune drugmaker Kira

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.  

By Delilah Alvarado • July 17, 2026

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.

By BioPharma Dive staff • July 17, 2026

How well are AI-discovered drugs faring in the clinic?

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.

By Kelly Bilodeau • July 17, 2026

Braveheart, Attovia join next wave of biotech IPOs

The heart drug developer and immune disease specialist aim to capitalize on momentum that’s already yielded several big-ticket IPOs this year.

By Gwendolyn Wu • July 15, 2026

J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

By Ben Fidler • July 15, 2026

Judge orders Apple Tree partner to forfeit oversight of venture fund

The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s portfolio companies.

By Gwendolyn Wu • Updated July 14, 2026

Draig bags another $65M to speed testing of brain drugs

The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder. 

By Delilah Alvarado • July 14, 2026

Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.

By Jacob Bell • July 14, 2026

Q32 bounces back to claim study success for alopecia drug

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

By Jonathan Gardner • July 13, 2026

Agenus surges on study pivot; Apnimed lines up an IPO

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

By Ben Fidler • July 13, 2026

Biotech startup funding gap widens despite rebound in VC investment

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

By Gwendolyn Wu • July 13, 2026

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.

By BioPharma Dive staff • July 10, 2026

Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal

An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for reviews.

By Ben Fidler • July 8, 2026

Oberland pours up to $400M into MeiraGTx eye gene therapies

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J. 

By Delilah Alvarado • July 7, 2026

Kailera says obesity pill succeeds in late-stage trial in China

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

By Jonathan Gardner • July 7, 2026

Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

By Ben Fidler • July 7, 2026